Rapid Eye Movement Sleep Behavior Disorder
10
1
4
1
Key Insights
Highlights
Success Rate
33% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 85/100
20.0%
2 terminated out of 10 trials
33.3%
-53.2% vs benchmark
10%
1 trials in Phase 3/4
0%
0 of 1 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (10)
[18F] - FD17 PET Imaging of α-synuclein: A Clinical Study in α-synucleinopathy Patients
A Clinical Study of the Efficacy of Idebenone in the Treatment of iRBD Into Synucleinopathies
Sleep Profiles in REM Sleep Behavior Disorder
Predictors Of Cognitive Decline Using Digital Devices
A Pilot Biomarker Study Assessing Alpha-synuclein Aggregates Across Biofluid Reservoirs in Patients With Synucleinopathies
Prodromal Model of Parkinson's Disease Confined to The Peripheral Nervous System
Multimodal Image Technologies Investigate the Role and Mechanism of Probiotics in Improving RBD with Parkinson's Disease
Effect of Acupuncture for Rapid Eye Movement Sleep Behavior Disorder
Extended-Release Melatonin in Patients With Rapid Eye Movement Sleep Behavior Disorder
RBD Longitudinal as Prognostic for PD